Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDMA +2 moremethylone, mephedrone, MDMA, amphetamine, cocaine show less
Ethylone
3,4-methylenedioxy-N-ethylcathinone
Ethylone (3,4-methylenedioxy-N-ethylcathinone) — also known as bk-MDEA — is a synthetic stimulant-entactogen of the cathinone class. It is a structural relative of methylone and the cathinone-class counterpart of MDEA. It blocks monoamine reuptake and actively releases serotonin, producing combined stimulant and emotionally opening effects.[1][2]
Ethylone (3,4-methylenedioxy-N-ethylcathinone) — also known as bk-MDEA — is a synthetic stimulant-entactogen of the cathinone class. It is the beta-keto structural analog of MDEA and the N-ethyl homolog of methylone, shorter-acting than MDMA. Ethylone inhibits monoamine reuptake and releases serotonin via substrate activity at the SERT, producing combined stimulant and entactogenic effects.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDMA +2 moremethylone, mephedrone, MDMA, amphetamine, cocaine show less
Ethylone emerged through clandestine chemical research around 2009–2010, first documented in a published metabolism review that same year.[3] It spread as part of the global "bath salts" wave of designer stimulants, appearing in US drug tests by early 2011.[4] It is now Schedule I in the United States and internationally controlled under the UN Convention on Psychotropic Substances.
Subjective effects include euphoria, enhanced sociability, emotional warmth, heightened energy, sensory brightness, and wakefulness.[5] The experience sits between a clean stimulant push and a mild MDMA-like emotional openness — shorter and less emotionally deep, with a prominent energy edge. Jaw clenching, anxiety, insomnia, and low mood in the days after use are common unsought effects.
No physical dependence data exist for ethylone, and no lethal dose or human overdose study has been published.[6][7] The primary dangers are cardiovascular stress and serotonin overload — both amplified by high doses or combination with other serotonin-raising drugs; the serotonin-dominant profile predicts lower compulsive redosing drive than more dopamine-focused cathinones.[8] The evidence base rests almost entirely on lab studies and structural analogy; no human clinical trials have been conducted.
History[edit]
Discovery
Ethylone is the N-ethyl homolog of methylone, which was first synthesized by Peyton Jacob III and Alexander Shulgin in the mid-1990s.[9] Ethylone itself has no documented original synthesis — it arose through clandestine structural variation, replacing methylone's N-methyl group with an N-ethyl group. No peer-reviewed publication covers its original creation.
Market emergence
Ethylone entered designer drug markets between 2009 and 2013 as part of the "bath salts" wave. Its earliest scientific mention appears in Meyer and Maurer's 2010 metabolism review under the name bk-MDEA,[3] and it was detected in US urine specimens beginning in February 2011.[4]
Scheduling
International controls followed quickly. The UK controlled all substituted cathinones as Class B in 2010; Australia banned ethylone in 2014.[5] The UN added it to Schedule II in March 2017,[10] and the US DEA issued a specific Schedule I listing in June 2020.[11]
The name ethylone follows systematic cathinone nomenclature: the "-one" suffix marks the beta-keto group, while "ethyl-" distinguishes it from Methylone. The alternate name bk-MDEA encodes the structural relationship — "bk" for beta-keto, "MDEA" for the non-keto parent compound. Ethylone has no widely recognized street names; it circulated primarily under its chemical identifiers in online research chemical markets and was frequently sold in "bath salt" blends without specific labeling.
Chemistry[edit]
Structural class
Ethylone is a methylenedioxy-substituted synthetic cathinone — a structural family defined by a beta-keto group on the side chain and a 3,4-methylenedioxy ring on the aromatic core (molecular formula C₁₂H₁₅NO₃, molecular weight 221.25 g/mol).
It is the direct beta-keto structural analog of MDEA and the N-ethyl homolog of methylone, differing from methylone by a single methylene unit on the amine nitrogen — a change that produces measurable differences in transporter activity.[2] The methylenedioxy ring is the same structural feature found in MDMA, which accounts for the entactogenic character shared across the methylenedioxy cathinone group.[10]
Pharmacology[edit]
Mechanism of action
Ethylone works through two simultaneous actions. It blocks the recycling of dopamine, norepinephrine, and serotonin — leaving them active in the synapse longer — while also actively pushing serotonin out of nerve terminals via the SERT.[1][2] The stimulant component comes from the reuptake-blocking action; the emotional warmth and sociability come from the active serotonin release.
Because serotonin release dominates over dopamine effects, ethylone drives less compulsive seeking behavior than cathinones that target dopamine more strongly — though the dopamine reuptake inhibitor still confers meaningful abuse potential.[8]
Pharmacokinetics
No human pharmacokinetic data have been published for ethylone. Based on the closely related methylone, oral onset likely occurs within 30–90 minutes and the parent compound clears with a half-life of roughly 60–90 minutes.[12] Metabolism has been mapped in human liver microsomes, with breakdown products serving as the primary markers in forensic urine testing.[13][4]
Neuroscience[edit]
Where it acts
Ethylone raises both dopamine and serotonin in the brain simultaneously. Dopamine elevation in the brain's reward circuit drives energy, motivation, and reinforcement.[9] Serotonin release across cortical and emotional circuits produces the warmth and sociability that distinguish entactogens from pure stimulants.
Why it matters
Dopamine and serotonin pull in different directions. Dopamine drives "wanting" — motivation and compulsive seeking. Serotonin shapes "liking" — the hedonic quality of an experience — and may actively dampen the dopamine wanting signal.[8] Ethylone's serotonin-leaning profile predicts an experience weighted toward warmth and connection rather than compulsive stimulation.
Critical questions about ethylone remain unanswered. The closely related methylone does not cause long-term serotonin depletion with repeated use[9] — whether ethylone shares this relative safety is unknown. No human dosing data exist; dose ranges circulating in harm reduction communities derive entirely from uncontrolled reports.safety citation needed
Subjective Effects[edit]
Ethylone produces a hybrid experience where stimulant energy and emotional warmth run together. The stimulant edge — focus, motivation, wakefulness — sits alongside an entactogenic softening: lowered emotional barriers, heightened sociability, and sensory richness. Social settings draw out the warmth; quieter, task-focused settings emphasize the stimulation.
Users familiar with MDMA generally find ethylone shorter, less emotionally immersive, and more energy-forward — the warmth is present but shallower. Compared to methylone, the two occupy similar pharmacological territory; both sit well removed from the purely stimulant character of dopamine-focused cathinones like MDPV.
Ethylone emerged through clandestine chemistry around 2009–2010, first named in a published metabolism review that same year.[3] It entered markets as part of the global "bath salts" wave, with detection in US urine specimens beginning in February 2011.[4] It is now Schedule I in the United States and Schedule II under the UN Convention on Psychotropic Substances.
Subjective effects include euphoria, enhanced sociability, sensory intensification, wakefulness, and bruxism.[5] The experience sits between a clean stimulant push and a muted MDMA-like emotional openness — shorter and less serotonergically deep, with a more prominent energy edge. Jaw clenching, anxiety, insomnia, and a post-use mood dip are common unsought effects.
No physical dependence data exist for ethylone, and no lethal dose, overdose case report, or controlled toxicity study has been published.[6][7] The primary acute risks are cardiovascular stress and serotonin syndrome — both amplified by high doses, redosing, or combination with other serotonergic agents, though the SERT-dominant profile predicts lower compulsive redosing potential than DAT-selective cathinones.[8] No clinical trials have been conducted; the entire evidence base rests on in vitro transporter studies and structural analog inference.
History[edit]
Discovery
The synthetic cathinone class descends from cathinone, the naturally occurring beta-keto amphetamine in Catha edulis (khat). Ethylone is the beta-keto structural analog of MDEA, described in Alexander Shulgin's PIHKAL, and the N-ethyl homolog of methylone, first synthesized by Peyton Jacob III and Alexander Shulgin in the mid-1990s.[9] No peer-reviewed publication documents ethylone's original synthesis — the compound arose through clandestine structural variation of the methylenedioxy cathinone scaffold, replacing methylone's N-methyl group with an N-ethyl group.
Market emergence
Ethylone entered designer drug markets as part of the "bath salts" wave between 2009 and 2013. The earliest scientific reference appears in Meyer and Maurer's 2010 metabolism review under the name bk-MDEA,[3] and detection in US urine specimens began in February 2011 from a screening cohort of over 34,000 samples.[4] The Australian Drug Foundation reported its appearance in the United States around late 2011.[5]
Scheduling
International scheduling followed rapidly. The United Kingdom controlled all substituted cathinones as Class B substances in 2010; Australia banned ethylone across multiple states in 2014.[5] The UN added ethylone to Schedule II of the 1971 Convention in March 2017,[10] and the US DEA published a specific Schedule I listing in June 2020, resolving prior legal ambiguity under the Federal Analogue Act.[11]
The name ethylone follows systematic cathinone nomenclature: the "-one" suffix denotes the beta-keto group shared by all cathinones, while "ethyl-" reflects the N-ethyl substituent that distinguishes it from Methylone (N-methyl). The alternate designation bk-MDEA explicitly encodes the structural relationship — "bk" for beta-keto, "MDEA" for 3,4-methylenedioxy-N-ethylamphetamine, the non-keto parent compound. Ethylone has no widely recognized street names; it circulated primarily under its chemical identifiers in online research chemical markets and was frequently sold in "bath salt" blends without specific labeling.
Chemistry[edit]
Structural class
Ethylone is a methylenedioxy-substituted synthetic cathinone — a beta-keto phenethylamine carrying a carbonyl group at the beta-carbon and a 3,4-methylenedioxy ring system. It shares this ring system with methylone, butylone, and — minus the beta-keto moiety — MDMA.
Structurally, ethylone is the direct beta-keto structural analog of MDEA: both carry the methylenedioxy ring and N-ethyl group, differing only by the beta-keto group that defines the cathinone class. It is simultaneously the N-ethyl homolog of Methylone, differing by one methylene unit on the amine nitrogen — a change that produces measurable differences in transporter selectivity and substrate activity.[2]
Molecular properties
| Molecular formula | C₁₂H₁₅NO₃ |
| Molecular weight | 221.25 g/mol |
The molecule comprises a 1,3-benzodioxole (methylenedioxy) ring connected via a propan-1-one bridge to an N-ethylamino group. The methylenedioxy moiety acts as a bioisostere for dihydroxy or dimethoxy substitution patterns found in other phenethylamines, conferring the pharmacological profile characteristic of MDMA-type entactogens.[10]
Stereochemistry
Ethylone has one chirality center at the alpha-carbon, producing R and S enantiomers. All published pharmacological work has used the racemic mixture. No enantioselective characterization exists for ethylone; by analogy with mephedrone, the S-enantiomer likely shows greater SERT potency while the R-enantiomer may drive stronger dopamine-mediated reinforcement.
Physical properties
Ethylone presents as clear crystals or white powder in its salt form.[5] No published melting point, solubility, or pKa data exist.
As a methylenedioxy cathinone, ethylone degrades more slowly in biological samples than non-methylenedioxy cathinones — a property of the electron-donating methylenedioxy ring.[12] Acidification of samples to pH <4 significantly improves analytical stability, a consideration relevant to forensic specimen handling.
Pharmacology[edit]
Mechanism of action
Ethylone operates through a dual mechanism: it blocks reuptake of dopamine, norepinephrine, and serotonin at their respective transporters while simultaneously acting as a substrate-type releaser specifically at the SERT (SERT).[1][2]
Simmler et al. classified ethylone among "Group 2 cathinones" — the MDMA-like subgroup that includes mephedrone, methylone, and butylone.[1] These compounds share high blood-brain barrier permeability, serotonin release through SERT substrate activity, and no activation of TAAR1 (TAAR1) — a key distinction from classical amphetamines and MDMA itself.
Eshleman et al. confirmed that ethylone releases serotonin as a substrate at human SERT but does not function as a substrate at human DAT or NET.[2] The stimulant component arises from reuptake inhibitor (blocking dopamine and norepinephrine clearance), while the entactogenic component arises from active serotonin efflux — a dual mechanism paralleling MDMA but from the cathinone scaffold.
The balance between these mechanisms matters for abuse potential. Cathinones with stronger DAT selectivity over SERT tend to be more reinforcing; ethylone's SERT-preferring profile predicts lower compulsive redosing drive than DAT-selective compounds like MDPV, while retaining reinforcing properties through dopamine reuptake inhibition.[8]
Pharmacokinetics
No human pharmacokinetic data have been published for ethylone. Parameters are inferred from Methylone, which differs only by an N-methyl versus N-ethyl substitution.
In rats, methylone reaches peak concentrations within 15–45 minutes after subcutaneous dosing (estimated 30–90 minutes orally in humans), with a parent compound half-life of approximately 60–90 minutes.[13] The pharmacokinetics are non-linear at higher doses, meaning blood levels rise disproportionately as dose increases.[13]
Ethylone-specific metabolism has been mapped in human liver microsomes. Primary Phase I pathways include N-dealkylation, beta-keto reduction, and demethylenation followed by O-methylation, with Phase II proceeding through glucuronide conjugation.[14] The beta-keto reduction products and demethylenation/O-methylation products serve as the most reliable urinary biomarkers for forensic detection.[14] Ethylone is also detectable as unchanged parent compound in free urine.[4]
Neuroscience[edit]
Where it acts
Ethylone's dual mechanism — dopamine/norepinephrine reuptake inhibitor plus serotonin release — activates two major brain systems simultaneously. Dopamine elevation in the mesolimbic mesolimbic pathway (ventral tegmental area to nucleus accumbens) drives the motivational, energizing, and reinforcing components. Serotonin efflux across cortical and limbic circuits activates postsynaptic serotonin receptors, producing the entactogenic effects: enhanced emotional processing, prosociality, and sensory richness.
The closely related compound methylone elevates both dopamine and serotonin in rat nucleus accumbens,[9] confirming dual monoaminergic activation in vivo. Stimulant locomotor effects in methylenedioxy cathinones involve 5-HT₂A receptor activation,[15] positioning this receptor as a key mediator of behavioral output beyond direct transporter effects.
Why it matters
The incentive salience model offers the most useful framework for understanding ethylone's profile. Dopamine elevation drives "wanting" (motivational salience and compulsive seeking), while serotonin release modulates "liking" (hedonic value) and may actively attenuate the dopaminergic wanting signal.[8] Ethylone's SERT-preferring profile predicts an experience weighted toward hedonic and empathogenic effects rather than compulsive stimulation.
The absence of TAAR1 activation[1] marks a qualitative difference from classical amphetamines and MDMA. TAAR1 modulates dopaminergic tone in those compounds; its absence in cathinones represents a pharmacologically distinct signature whose experiential consequences remain unstudied.
Several fundamental questions about ethylone remain unanswered. Methylone does not cause long-term serotonin depletion despite repeated dosing,[9] unlike MDMA — whether ethylone shares this relative safety is unknown. No study has separated ethylone's R and S enantiomers, leaving the contribution of each to abuse liability and serotonergic effects unclear.
Subjective Effects[edit]
Ethylone produces a hybrid stimulant-entactogenic experience whose character shifts with dose, neurochemistry, and context. At lower doses, the stimulant edge predominates — energy, wakefulness, and focused motivation. As dose increases, serotonergic warmth emerges: emotional openness, enhanced sociability, and sensory richness. Social environments tend to draw out the empathogenic character, while solo or task-focused settings emphasize stimulation. Set and setting exert strong influence on the overall emotional tone.
Users familiar with MDMA generally describe ethylone as shorter, less emotionally deep, and more stimulant-forward — the warmth is present but shallower, the energy more prominent. Compared to methylone, which has more balanced transporter substrate activity, ethylone occupies a similar pharmacological space but sits further from the purely stimulant character of DAT-selective cathinones like MDPV.
Effect Grid
At common doses (125–200 mg oral), the full entactogenic-stimulant experience manifests. Euphoria is prominent, accompanied by enhanced sociability, emotional openness, and empathogenic warmth toward others. Music enhancement becomes pronounced, and touch enhancement is clearly present. Sensory perception is heightened across modalities — visual brightening, mild visual haze, and intensified auditory experience. Thought acceleration is marked, with increased motivation and engagement.
Physically, stimulation is strong: elevated heart rate, bruxism (jaw clenching), appetite suppression, wakefulness, and sexual arousal enhancement. Temperature dysregulation becomes a genuine concern — users feel warm and may sweat.
The experience commits the user for approximately 2–4 hours of active effects, with an additional period of residual stimulation and mood shift. Sleep is impossible during active effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Light sensitivity · Sound sensitivity · Brightness alteration · Color alteration
Body high · Dry mouth · Pupil dilation · Spontaneous body sensations · Dehydration sensation · Excessive sweating · Bruxism · Insomnia · Muscle tension · Physical fatigue · Restlessness · Tactile euphoria · Sexual arousal enhancement · Heart rate perception changes · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Bodily lightness · Dizziness · Headache · Nausea · Respiratory stimulation · Increased urination · Abnormal heartbeat · Nystagmus (eye wobbles)
Spontaneous body sensations · Dehydration sensation · Excessive sweating · Bruxism · Insomnia · Muscle tension · Physical fatigue · Restlessness · Tactile euphoria · Sexual arousal enhancement · Heart rate perception changes · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Bodily lightness · Dizziness · Headache · Nausea · Respiratory stimulation · Increased urination · Nystagmus (eye wobbles)
Openness enhancement · Motivation suppression · Aesthetic enhancement · Humor enhancement · Immersion enhancement · Introspection enhancement · Creativity enhancement · Motivation enhancement · Analysis suppression · Cognitive flexibility · Memory suppression · Novelty enhancement · Suggestibility enhancement · Thought connectivity · Analysis enhancement · Focus enhancement · Information processing enhancement · Language enhancement · Thought deceleration · Cognitive impairment · Memory fragmentation
Humor enhancement · Immersion enhancement · Introspection enhancement · Creativity enhancement · Motivation enhancement · Analysis suppression · Cognitive flexibility · Memory suppression · Novelty enhancement · Thought connectivity · Analysis enhancement · Focus enhancement · Information processing enhancement · Language enhancement · Thought deceleration · Cognitive impairment · Memory fragmentation
Irritability · Anxiety · Anhedonia · Anxiety suppression · Dysphoria · Emotional lability · Simultaneous emotions · Catharsis
Dysphoria · Emotional lability · Simultaneous emotions · Catharsis
Communication enhancement · Emotional susceptibility · Craving · Flow state · Boundary dissolution
Boundary dissolution
Timeline
First alerts emerge as mild restlessness and subtle mood lift. Physical awareness increases slightly — a faint warmth or tingling sensation may be noticed.
Stimulation builds progressively with rising heart rate, jaw tension onset, and emerging sociability. Sensory enhancement begins — music sounds richer, tactile sensitivity increases.
Maximum entactogenic and stimulant effects: pronounced euphoria, emotional openness, enhanced sociability, strong sensory intensification. Bruxism, tachycardia, and temperature dysregulation are at their most prominent.
Effects sustain at reduced intensity. Entactogenic warmth persists while stimulant edge softens. Cognitive clarity begins to return though sensory enhancement remains.
Gradual return toward baseline. Residual stimulation and mild mood elevation continue. Physical effects (jaw tension, elevated heart rate) diminish.
Residual effects include mild fatigue, subdued mood, and possible irritability as monoamine levels normalize. Some users report lingering warmth and reflectiveness; others experience low mood and anxiety.
⚠ Do not drive or operate machinery until after a full night of sleep, as residual stimulant effects and fatigue may impair reaction time and judgment.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDMA
Toxicity
Acute toxicity
No lethal dose, animal toxicology study, or human overdose case report has been published for ethylone. This reflects its relative rarity in surveillance data — not confirmed safety.
Class-level risks for synthetic cathinones include rapid heart rate, elevated blood pressure, and rare heart attack,[7] plus serotonin syndrome at high doses — dangerous overheating, metabolic acidosis, and muscle breakdown.[6][14]
Heart and circulation
Elevated heart rate and blood pressure are expected consequences of blocking dopamine and norepinephrine clearance. Irregular heartbeat has been reported.[5] Heart attack has been documented with cathinone class agents in rare cases.[7]
Serotonin toxicity
At high doses or combined with other serotonergic agents, ethylone carries risk of serotonin syndrome — a potentially fatal condition involving dangerous overheating, muscle rigidity, and altered consciousness. No specific antidote exists; treatment is supportive.[6][7]
Overdose can present with severe headache, dangerously high body temperature, dehydration, agitation, hallucinations, psychosis, and seizures; ethylone can cause death.[5]
After-effects
The days after use commonly bring anxiety, fatigue, insomnia, depression, and irritability.[5] These follow predictably from temporary serotonin depletion after serotonin release.
Psychological risks
No ethylone-specific psychiatric data exist. Across the synthetic cathinone class, documented adverse effects include agitation, anxiety, paranoia, hallucinations, acute psychosis, and seizures.[15]
Ethylone's serotonin-dominant profile means psychiatric risks lean toward mood instability and anxiety rather than the dopamine-driven paranoid psychosis seen with more stimulant-focused cathinones. Chronic use can still produce persistent paranoid ideation.[15]
Tolerance & dependence
No published tolerance or dependence data exist for ethylone. Tolerance is expected with repeated use through transporter desensitization, with cross-tolerance plausible to other stimulants and serotonin-releasing agents.
Structural analogs — methylone, butylone, pentylone — are reliably self-administered in animal models.[16] Ethylone's serotonin-dominant profile predicts lower reinforcing effectiveness than dopamine-selective cathinones, but the dopamine component still confers meaningful abuse potential.[8][1]
Drug Interactions
Tramadol blocks the SERT.[17][18] Combined with ethylone's serotonin-releasing activity,[2] this creates additive serotonergic burden with a direct pathway to serotonin syndrome.
MAOIs block serotonin breakdown. Combined with ethylone's serotonin release, dangerous — potentially fatal — serotonin accumulation results.
SSRIs and SNRIs add serotonergic load and may also blunt ethylone's entactogenic effects by occupying the serotonin transporter.
MDMA and other serotonergic entactogens produce additive serotonergic burden with elevated risk of overheating and serotonin syndrome.[1]
Alcohol may mask the perceived stimulant effect, increasing dose escalation risk; combined cardiovascular stress is unpredictable.
Contraindications
7 knownHeart conditions: Elevated heart rate and blood pressure are class effects. Pre-existing cardiovascular disease increases acute cardiac event risk.[7]
Psychotic disorders: Synthetic cathinones produce paranoid ideation, hallucinations, and acute psychosis.[15] Pre-existing psychotic vulnerability substantially amplifies this risk.
Concurrent MAOI use: Absolute contraindication — life-threatening serotonin syndrome risk.
Concurrent serotonergic medications (SSRIs, SNRIs, tramadol): Serotonin syndrome risk via additive serotonergic load.[17][18]
Seizure disorders: Seizures are documented across the cathinone class.[15]
Pregnancy and breastfeeding: No reproductive toxicity data exist. Stimulant and serotonergic activity represent theoretical risks to fetal development.safety citation needed
Harm Reduction[edit]
Forms & Identification
Ethylone typically appears as white powder or clear crystals.[5] Synthetic cathinones are visually indistinguishable from one another; reagent testing can narrow possibilities but cannot confirm identity. Laboratory analysis through a drug checking service is the only reliable identification method.
Cathinone products are frequently mislabeled or contain mixtures. Testing is not optional — it is the minimum threshold for informed dosing.
Guidelines
- Test every batch with a reagent kit and, where available, a drug checking service. Visual inspection cannot distinguish ethylone from more dangerous cathinones.
- Start with a low dose and wait at least 90 minutes before considering redosing. Oral onset can be slow, and premature redosing is the most common path to excessive stimulation.
- Weigh doses with a milligram-precision scale. Volumetric estimation of powder is unreliable.
- Stay hydrated but avoid overhydration — sip water steadily rather than drinking large amounts. Serotonergic stimulants can impair the body's fluid regulation.
- Eat a light meal beforehand. Stimulant appetite suppression combined with physical activity increases dehydration and exhaustion risk.
- Have a sober, trusted person present who knows what has been taken.
Set & Setting
Ethylone's effects are strongly context-dependent. Social environments amplify the entactogenic warmth; isolated settings may foreground stimulant anxiety. A comfortable, familiar environment with trusted people reduces the likelihood of anxiety escalation.
The duration is relatively short, but the stimulant tail may extend beyond the primary effects. Adequate time for wind-down and sleep before obligations matters.
Aftercare & integration. The days following ethylone use commonly involve low mood, fatigue, irritability, and disrupted sleep — a predictable consequence of temporary serotonin depletion. These effects typically resolve within 2–4 days.
- Sleep: Prioritize rest. The stimulant tail may make the first night difficult; avoid using additional substances to force sleep.
- Nutrition: Eat balanced meals even if appetite is reduced. Tryptophan-rich foods support natural serotonin recovery.
- Activity: Light exercise can improve mood during the recovery window. Avoid intense exertion for 24–48 hours.
- Reflection: If the experience produced emotional material — particularly if entactogenic effects were prominent — journaling or conversation with a trusted person can help process it.
If low mood, anxiety, or sleep disruption persists beyond a week, consult a healthcare provider.
Recovery & Support
Ethylone's serotonin-dominant profile may produce lower compulsive redosing drive than dopamine-selective stimulants, but repeated use still carries dependence risk. Warning signs include escalating frequency, difficulty maintaining commitments, using alone, and continuing despite negative consequences.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local drug and alcohol services, and peer support communities. Cognitive behavioral therapy has established efficacy for stimulant use disorders. Early intervention produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most ethylone experiences involve manageable discomfort. The following signs require immediate medical help:
- Chest pain, crushing pressure, or sudden sharp pain in the left arm or jaw
- Seizures or uncontrollable muscle rigidity
- Body temperature hot enough to feel through clothing — dangerous overheating
- Loss of consciousness or unresponsiveness
- Severe confusion, psychosis, or self-harm behavior
- Irregular or very rapid heartbeat that does not slow with rest
Immediate steps
- 1. Call emergency services immediately if any of the above are present.
- 2. Move the person to a cool, quiet area. Remove excess clothing if overheating.
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear).
- 4. Do not restrain the person unless they are in immediate physical danger.
- 5. Do not induce vomiting.
- 6. Stay with them until help arrives.
What to tell the dispatcher
State what was taken (ethylone or synthetic cathinone), the approximate amount and time, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency — do not let fear of legal consequences delay the call.
Legal Status[edit]
Ethylone is controlled in all major jurisdictions, following scheduling actions between 2010 and 2020 that targeted the synthetic cathinone class broadly.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II — 1971 Convention on Psychotropic Substances | Added March 2017 at the 60th Session of the Commission on Narcotic Drugs; CAS 1112937-64-0[10] |
| United States | Schedule I (Controlled Substances Act) | Specific listing effective June 8, 2020; CSA code 7547. Previously controlled under the Federal Analogue Act as a positional isomer of butylone[11] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | All substituted cathinones controlled via generic ban, effective 2010 |
| Australia | Controlled substance (state-based) | Banned in Queensland, New South Wales, South Australia, and Victoria[5] |
| WADA | Specified stimulant | Prohibited in competition; synthetic cathinone class[19] |
Scheduling status changes over time. This table reflects known classifications as of 2026 and does not constitute legal advice.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDMA
Toxicity
Acute toxicity
No lethal dose, animal toxicology study, or human overdose case report specific to ethylone has been published. This absence reflects low surveillance prevalence compared to cathinones like methylone and MDPV — it does not indicate safety.
Class-level risks for synthetic cathinones include rapid heart rate, elevated blood pressure, and rare heart attack,[7] as well as serotonin syndrome at high doses — dangerous overheating, metabolic acidosis, and muscle breakdown.[6][16]
Heart and circulation
Elevated heart rate and blood pressure are expected consequences of dopamine and norepinephrine reuptake inhibitor. Irregular heartbeat has been reported.[5] Heart attack has been documented with cathinone class agents in rare cases.[7]
Serotonin toxicity
At high doses or combined with other serotonergic agents, ethylone carries risk of serotonin syndrome — a potentially fatal condition involving dangerous overheating, muscle rigidity, and altered consciousness. No specific antidote exists; treatment is supportive.[6][7]
The Australian Drug Foundation states that ethylone overdose can present with severe headache, irregular heartbeat, dangerously high body temperature, dehydration, nausea, agitation, anxiety, hallucinations, psychosis, and seizures, and that ethylone can cause death.[5]
After-effects
Post-use effects include anxiety, fatigue, insomnia, depression, and irritability persisting for days.[5] These are consistent with temporary monoamine depletion following serotonin release.
Psychological risks
No ethylone-specific psychiatric data exist. For the synthetic cathinone class, documented adverse effects include agitation, anxiety, paranoia, hallucinations, acute psychosis, and seizures.[17]
Ethylone's serotonin-dominant profile suggests psychiatric risks weight toward mood instability, anxiety, and emotional lability rather than the dopamine-driven stimulant psychosis characteristic of DAT-selective agents like MDPV. Chronic cathinone use can produce persistent paranoid ideation and delusions, particularly with high-potency stimulant cathinones.[17]
Tolerance & dependence
No published tolerance or dependence studies exist for ethylone. Tolerance is expected to develop through monoamine transporter desensitization with repeated use, with cross-tolerance plausible across other stimulants and serotonin-releasing agents.
Structural analogs (methylone, butylone, pentylone) are robustly self-administered in animal models.[18] The DAT/SERT ratio framework predicts ethylone has lower reinforcing effectiveness than DAT-selective cathinones but retains meaningful abuse potential.[8] Simmler et al. noted that cathinone action at the dopamine transporter is "probably associated with a considerable risk of addiction".[1]
Drug Interactions
Tramadol inhibits the serotonin transporter.[19][20] Combined with ethylone's serotonin-releasing activity,[2] this creates additive serotonergic burden with a defined pathway to serotonin syndrome.
MAOIs are contraindicated with all serotonin-releasing agents. Blocking serotonin breakdown while ethylone drives serotonin release produces dangerous and potentially fatal serotonin accumulation.
SSRIs and SNRIs create additive serotonergic risk and may also blunt ethylone's entactogenic effects through competitive occupancy at SERT.
MDMA and other serotonergic entactogens combined with ethylone produce additive serotonergic burden with elevated risk of overheating and serotonin syndrome.[1]
Alcohol may mask perceived stimulant effects, increasing dose escalation risk, while combined cardiovascular stress is unpredictable.
Contraindications
7 knownHeart conditions: Elevated heart rate and blood pressure are class effects. Pre-existing cardiovascular disease increases acute cardiac event risk.[7]
Psychotic disorders: Synthetic cathinones produce paranoid ideation, hallucinations, and acute psychosis.[17] Pre-existing psychotic vulnerability substantially amplifies this risk.
Concurrent MAOI use: Absolute contraindication — life-threatening serotonin syndrome risk.
Concurrent serotonergic medications (SSRIs, SNRIs, tramadol): Serotonin syndrome risk via additive serotonergic load.[19][20]
Seizure disorders: Seizures are documented across the cathinone class.[17]
Pregnancy and breastfeeding: No reproductive toxicity data exist. Stimulant and serotonergic activity represent theoretical risks to fetal development.safety citation needed
Harm Reduction[edit]
Forms & Identification
Ethylone typically appears as white powder or clear crystals.[5] Because synthetic cathinones are visually indistinguishable from one another, reagent testing alone cannot confirm identity — it can only narrow the possibilities. Laboratory analysis through a drug checking service provides the only reliable identification. Given that cathinone products are frequently mislabeled or contain mixtures, testing is not optional — it is the minimum threshold for informed dosing.
Guidelines
- Test every batch with a reagent kit and, where available, a drug checking service. Visual inspection cannot distinguish ethylone from more dangerous cathinones.
- Start with a low dose and wait at least 90 minutes before considering redosing. Oral onset can be slow, and premature redosing is the most common path to excessive stimulation.
- Weigh doses with a milligram-precision scale. Volumetric estimation of powder is unreliable.
- Stay hydrated but avoid overhydration — sip water steadily rather than drinking large amounts. Serotonergic stimulants can impair the body's fluid regulation.
- Eat a light meal beforehand. Stimulant appetite suppression combined with physical activity increases dehydration and exhaustion risk.
- Have a sober, trusted person present who knows what has been taken.
Set & Setting
Ethylone's effects are strongly context-dependent. Social environments tend to amplify the entactogenic warmth, while isolated settings may foreground stimulant anxiety. A comfortable, familiar environment with trusted people reduces the likelihood of anxiety escalation.
Because the duration is relatively short, planning is straightforward — but the stimulant tail may extend beyond the primary effects. Ensure adequate time for wind-down and sleep before obligations.
Aftercare & integration. The days following ethylone use commonly involve low mood, fatigue, irritability, and disrupted sleep — a predictable consequence of temporary serotonin depletion. These effects typically resolve within 2–4 days.
- Sleep: Prioritize rest. The stimulant tail may make the first night difficult; avoid using additional substances to force sleep.
- Nutrition: Eat balanced meals even if appetite is reduced. Tryptophan-rich foods support natural serotonin recovery.
- Activity: Light exercise can improve mood during the recovery window. Avoid intense exertion for 24–48 hours.
- Reflection: If the experience produced emotional material — particularly if entactogenic effects were prominent — journaling or conversation with a trusted person can help process it.
If low mood, anxiety, or sleep disruption persists beyond a week, consult a healthcare provider.
Recovery & Support
Ethylone's serotonin-dominant profile may produce lower compulsive redosing drive than DAT-selective stimulants, but repeated use still carries dependence risk. Warning signs include escalating frequency, difficulty maintaining commitments, using alone, and continuing despite negative consequences.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local drug and alcohol services, and peer support communities. Cognitive behavioral therapy has established efficacy for stimulant use disorders. Early intervention produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most ethylone experiences involve manageable discomfort. The following signs require immediate medical help:
- Chest pain, crushing pressure, or sudden sharp pain in the left arm or jaw
- Seizures or uncontrollable muscle rigidity
- Body temperature hot enough to feel through clothing — dangerous overheating
- Loss of consciousness or unresponsiveness
- Severe confusion, psychosis, or self-harm behavior
- Irregular or very rapid heartbeat that does not slow with rest
Immediate steps
- 1. Call emergency services immediately if any of the above are present.
- 2. Move the person to a cool, quiet area. Remove excess clothing if overheating.
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear).
- 4. Do not restrain the person unless they are in immediate physical danger.
- 5. Do not induce vomiting.
- 6. Stay with them until help arrives.
What to tell the dispatcher
State what was taken (ethylone or synthetic cathinone), the approximate amount and time, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency — do not let fear of legal consequences delay the call.
Legal Status[edit]
Ethylone is controlled under international drug scheduling frameworks and prohibited in all major jurisdictions. Its regulatory trajectory follows the broader synthetic cathinone class, which was subject to emergency and generic scheduling actions worldwide between 2010 and 2020.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II — 1971 Convention on Psychotropic Substances | Added March 2017 at the 60th Session of the Commission on Narcotic Drugs; CAS 1112937-64-0[10] |
| United States | Schedule I (Controlled Substances Act) | Specific listing effective June 8, 2020; CSA code 7547. Previously controlled under the Federal Analogue Act as a positional isomer of butylone[11] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | All substituted cathinones controlled via generic ban, effective 2010 |
| Australia | Controlled substance (state-based) | Banned in Queensland, New South Wales, South Australia, and Victoria[5] |
| WADA | Specified stimulant | Prohibited in competition; synthetic cathinone class[21] |
Prior to the June 2020 specific listing, ethylone's US legal status rested on the Federal Analogue Act (21 U.S.C. § 813), which extends Schedule I/II controls to substances "substantially similar" in structure or effect to a listed substance when intended for human consumption. The 2020 DEA action eliminated this ambiguity by establishing a substance-specific Schedule I classification with a dedicated CSA code.
Frequently asked questions
What is Ethylone?
Ethylone is a synthetic cathinone with stimulant and entactogenic properties, also known as bk-MDEA, scheduled internationally since 2017. It acts as a non-selective monoamine reuptake inhibitor and selective serotonin releaser at SERT, with no established clinical use.
How long does Ethylone last?
Total duration by route of administration — Oral: 2 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Ethylone?
Psychedex publishes a dosage table for Ethylone on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Ethylone?
The highest-severity documented interactions for Ethylone: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Ethylone addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Ethylone: tolerance builds moderate; full reset takes 10 days; cross-tolerance develops with methylone, mephedrone, MDMA, amphetamine, cocaine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [2] ^abcdEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A (2017) Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release — Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.116.236349
- [3] ^abMeyer MR, Maurer HH (2010) Metabolism of designer drugs of abuse: an updated review — Current Drug Metabolism PMID:20540700
- [4] ^abcUralets V, Rana S, Morgan S, Ross W (2014) Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. — Journal of Analytical Toxicology doi:10.1093/jat/bku021
- [5]
- [6] ^abcDebruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J (2014) Emerging drugs of abuse: current perspectives on substituted cathinones — Substance Abuse and Rehabilitation doi:10.2147/sar.s37257
references
- [1]
- [2]
- [3] ^abMeyer MR, Maurer HH (2010) Metabolism of designer drugs of abuse: an updated review — Current Drug Metabolism PMID:20540700
- [4] ^abcUralets V, Rana S, Morgan S, Ross W (2014) Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. — Journal of Analytical Toxicology doi:10.1093/jat/bku021
- [5]
- [6] ^abcDebruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J (2014) Emerging drugs of abuse: current perspectives on substituted cathinones — Substance Abuse and Rehabilitation doi:10.2147/sar.s37257